The IHE Diabetes Cohort Model was recently used in the reimbursement application for Ozempic (semaglutide) in Norway. The Norwegian Medicines Agency (NoMA) discusses advantages and disadvantages of cohort simulation compared to micro simulation and concludes that cohort modelling may be suitable for health-economic analysis of type 2 diabetes (T2DM).
“Markov cohort modeling is a common and well-established method for health economics analyzes. For T2DM, micro-simulation (simulates at individual level) is considered more suitable due to the complexity of the course of disease. Such models are often heavy to run and less transparent than cohort level simulation. The cohort model loses some accuracy, but this is compensated by a much faster model. A shorter run time simplifies validation of the model and the running of sensitivity analyzes. The Norwegian Medicines Agency considers that it may be appropriate with cohort modeling of T2DM (faster run time), even if it loses some accuracy. Lundqvist et al. demonstrated that the results from the cohort model were comparable to other established models. It is also positive that all baseline patient characteristics and treatment effects (change in biomarkers e.g. HbA1c) can easily be changed in the model.” Translated from Norwegian, The Norwegian Medicines Agency.
The model was also recently used for cost-effectiveness analyses in Canadian and Swedish settings; two applications which were published in the peer-reviewed journals PharmacoEconomics – Open (Johansen et al. 2019) and Journal of Medical Economics (Ericsson et al. 2019).
The IHE Diabetes Cohort Model is a health-economic simulation model that analyses the cost-effectiveness of treatments for T2DM. The model can be used for individual projects by the IHE team or licensed on an annual basis.
For more information, please contact Sofie Persson